Clinical Trial

A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL

Name: A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL — clinical trial record (NCT07170254)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 infection.

Trial Details

NCT Number	NCT07170254
Lead Sponsor	Shanghai BDgene Co., Ltd. Collaborators: Obstetrics & Gynecology Hospital of Fudan University
Conditions	High-grade Squamous Intraepithelial Lesions (HSIL)
Enrollment	12 participants
Start Date	2025-09
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-12